Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: Arthritis Care Res (Hoboken). 2022 Jan 28;74(3):371–376. doi: 10.1002/acr.24496

Figure 1: Proportion of sarcoidosis patients prescribed a biologic or targeted synthetic DMARD by practice (n=31) in the RISE registry.

Figure 1:

Each bar represents a different practice with at least 30 patients with sarcoidosis. The figure shows that biologics use among these practices ranged from 15.6% to 69.2% of sarcoidosis patients.